Our latest COVID-19 information - now taking bookings for online webinar courses

Pharmaceutical Regulatory Affairs in the Middle East, Dubai Training Course

This seminar will provide you with an essential overview of the key areas of pharmaceutical regulatory affairs in the Middle East.

Course Overview

This two-day seminar will provide you with an essential overview of the key areas of pharmaceutical regulatory affairs in the Middle East to help you navigate the challenges and demands of this fast-growing market. The programme will focus on practical aspects and will cover the regulatory requirements and developments in individual countries as well as harmonisation across the region. Interactive discussion sessions will allow you to exchange experiences with our experienced trainers and other delegates.

Countries to be covered include Bahrain, Egypt, Iran, Iraq, Jordan, Kuwait, Lebanon, Libya, Oman, Palestine, Qatar, Saudi Arabia, Sudan, Syria, UAE, Yemen

Why you should attend

  • Gain an overview of the regulatory environment in the Middle East
  • Understand the economic and cultural background to the markets
  • Clarify procedures for company and product registration
  • Discuss harmonisation and recent developments in the region ** Centralised registration in the Gulf (GCC-DR), Middle East Regulatory Conference (MERC) ** MERC follow-up activities ** Industry regulatory groups and activities
  • Opportunities to meet, network and share experiences with other industry colleagues

Who should attend

  • Anyone involved in pharmaceutical regulatory affairs in the Middle East
  • Anyone new to the region
  • Anyone interested in an update on recent developments

Programme

Economic overview of the Middle East

  • Population and GDP per capita
  • Unemployment rate
  • GDP real growth rate
  • Inflation rate
  • Healthcare spend per capita

The pharmaceutical regulatory environment in the Middle East – individual presentations will be given on the following regions:

  • Bahrain
  • Egypt
  • Iran
  • Iraq
  • Kuwait
  • Lebanon
  • Libya
  • Oman
  • Palestine
  • Qatar
  • Saudi Arabia
  • Sudan
  • UAE
  • Yemen
  • Syria
  • Jordan

Each regional presentation will cover:

  • Markets and culture
  • Healthcare
  • Business culture
  • Regulatory environment and characteristics
  • General regulatory requirements
  • Company and product registration
  • Variations and renewals
  • Regulatory summary
  • Practical advice on registration in each region
Harmonisation and recent developments
  • Centralised registration in the Gulf
    • Gulf Central Committee for Drug Registration (GCC-DR)
    • SGH Tender
  • Middle East Regulatory Conference (MERC)
  • MERC follow-up activities
  • Industry regulatory groups and activities
  • Local trade associations

Final discussion and objectives review

Book now

We do not currently have dates confirmed for this course; please contact us to be informed when it is scheduled; or to discuss running this course on an in-house basis for your staff.

You may also be interested in

Previous customers include...

  • Aspen
  • Cesra Arzneimittel GmbH & Co. KG
  • Eli Lilly SA
  • Minamas Company
  • MS Pharma Jordan
  • Novo Nordisk A/S

So helpful and useful

Badr Mohammed Arafah, Manager, Eli Lilly SA, Oct 17

Everything was excellent

Majed Almajed, RA Associate, Aspen, Oct 17

So helpful and useful

Badr Mohammed Arafah, Manager, Eli Lilly SA, Oct 17

Very informative, good discussions, details etc

Lizzie Bejstrup Nielsen, Senior Regulatory Country Coordinator, Novo Nordisk A/S, Oct 17

Everything was excellent.

Majed Almajed, RA Associate, Aspen, Oct 17

The course and everything was very good, enjoyable and helpful

Raghad Mousa, RA Officer, MS Pharma Jordan, Oct 17

It was an interesting [and] helpful experience.

Raghad Mousa, RA Officer, MS Pharma Jordan, Oct 17

It was very good.

Lizzie Bejstrup Nielsen, Senior Regulatory Country Coordinator, Novo Nordisk A/S, Oct 17

Good overview and easy to understand

Benedicte Brask, Senior Regulatory Country Coordinator, Novo Nordisk A/S, Oct 17